{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:10Z","timestamp":1790710090218,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02547-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:03:32Z","timestamp":1768025012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Olivier","family":"Castellanet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Monatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Corvaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdessamad El","family":"Kaoutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muge","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lor\u00e8ne","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Camoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de Nonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Michea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Lamballe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2547_CR1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv048","volume":"107","author":"BA Kohler","year":"2015","unstructured":"Kohler BA, et al. Annual report to the nation on the status of cancer, 1975\u20132011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.","journal-title":"J Natl Cancer Inst"},{"key":"2547_CR2","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:5652\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2547_CR3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15:1796.","journal-title":"Pharmaceutics"},{"key":"2547_CR4","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, A. & Nonneville, A. de. Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer. Lancet Oncol. 26, 273\u2013274 (2025).","DOI":"10.1016\/S1470-2045(25)00028-2"},{"key":"2547_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PPO.0000000000000499","volume":"27","author":"RM Layman","year":"2021","unstructured":"Layman RM, Arun B. PARP inhibitors in triple-negative breast cancer including those with BRCA mutations. Cancer J. 2021;27:67\u201375.","journal-title":"Cancer J"},{"key":"2547_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"2547_CR7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"2547_CR8","doi-asserted-by":"crossref","first-page":"1447280","DOI":"10.3389\/fimmu.2024.1447280","volume":"15","author":"V Rossi","year":"2024","unstructured":"Rossi V, Turati A, Rosato A, Carpanese D. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back. Front Immunol. 2024;15:1447280.","journal-title":"Front Immunol"},{"key":"2547_CR9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.21037\/atm-22-813","volume":"10","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, Goncalves A, Mamessier E, Bertucci F. Sacituzumab govitecan in triple-negative breast cancer. Ann Transl Med. 2022;10:647.","journal-title":"Ann Transl Med"},{"key":"2547_CR10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med"},{"key":"2547_CR11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet"},{"key":"2547_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:405\u201311.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2547_CR13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499\u2013511.","journal-title":"Lancet Oncol"},{"key":"2547_CR14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"2547_CR15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"2547_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"},{"key":"2547_CR17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"2547_CR18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10549-011-1554-7","volume":"132","author":"M Ono","year":"2012","unstructured":"Ono M, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793\u2013805.","journal-title":"Breast Cancer Res Treat"},{"key":"2547_CR19","volume":"28","author":"S Loi","year":"2017","unstructured":"Loi S, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. 2017;28:v608.","journal-title":"Ann Oncol"},{"key":"2547_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00721-2","author":"NAM Bakker","year":"2025","unstructured":"Bakker NAM, et al. Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality. NPJ Breast Cancer. 2025. https:\/\/doi.org\/10.1038\/s41523-025-00721-2.","journal-title":"NPJ Breast Cancer"},{"key":"2547_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2017.09.035","volume":"222","author":"W Zhang","year":"2018","unstructured":"Zhang W, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res. 2018;222:93\u2013101.","journal-title":"J Surg Res"},{"key":"2547_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07789-6","author":"S-K Geng","year":"2021","unstructured":"Geng S-K, Fu S-M, Ma S-H, Fu Y-P, Zhang H-W. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer. 2021. https:\/\/doi.org\/10.1186\/s12885-021-07789-6.","journal-title":"BMC Cancer"},{"key":"2547_CR23","doi-asserted-by":"publisher","unstructured":"Yuan, Z.-Y., Luo, R.-Z., Peng, R.-J., Wang, S.-S. & Xue, C. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets Ther. 1475 (2014) https:\/\/doi.org\/10.2147\/ott.s61838.","DOI":"10.2147\/ott.s61838"},{"key":"2547_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00267-x","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. Tumor-derived HMGB1 induces CD62Ldim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer. Oncogenesis. 2020. https:\/\/doi.org\/10.1038\/s41389-020-00267-x.","journal-title":"Oncogenesis"},{"key":"2547_CR25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","volume":"21","author":"IS Kim","year":"2019","unstructured":"Kim IS, et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019;21:1113\u201326.","journal-title":"Nat Cell Biol"},{"key":"2547_CR26","volume":"6","author":"ES Seo","year":"2025","unstructured":"Seo ES, et al. Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype. Cell Rep Med. 2025;6:102164.","journal-title":"Cell Rep Med"},{"key":"2547_CR27","doi-asserted-by":"crossref","first-page":"1513421","DOI":"10.3389\/fimmu.2024.1513421","volume":"15","author":"L Serrano Garc\u00eda","year":"2024","unstructured":"Serrano Garc\u00eda L, et al. Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review. Front Immunol. 2024;15:1513421.","journal-title":"Front Immunol"},{"key":"2547_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217865","volume":"628","author":"H Sabit","year":"2025","unstructured":"Sabit H, et al. The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities. Cancer Lett. 2025;628:217865.","journal-title":"Cancer Lett"},{"key":"2547_CR29","volume":"11","author":"Y Fan","year":"2015","unstructured":"Fan Y, et al. Tissue-specific gain of RTK signalling uncovers selective cell vulnerability during embryogenesis. PLoS Genet. 2015;11:e1005533.","journal-title":"PLoS Genet"},{"key":"2547_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.11","volume":"2","author":"M Genestine","year":"2011","unstructured":"Genestine M, et al. Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Dis. 2011;2:e130.","journal-title":"Cell Death Dis"},{"key":"2547_CR31","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003049","volume":"8","author":"F Lamballe","year":"2021","unstructured":"Lamballe F, et al. Modeling heterogeneity of triple-negative breast cancer uncovers a novel combinatorial treatment overcoming primary drug resistance. Adv Sci. 2021;8:2003049.","journal-title":"Adv Sci"},{"key":"2547_CR32","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.7150\/thno.60503","volume":"11","author":"O Castellanet","year":"2021","unstructured":"Castellanet O, et al. Bcl-xl blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics. 2021;11:9180\u201397.","journal-title":"Theranostics"},{"key":"2547_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S316700","volume":"14","author":"Y Fan","year":"2022","unstructured":"Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022;14:1\u201317.","journal-title":"Cancer Manag Res"},{"key":"2547_CR34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia Y, et al. Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion. Cell Commun Signal. 2025;23:46.","journal-title":"Cell Commun Signal"},{"key":"2547_CR35","doi-asserted-by":"crossref","first-page":"1498391","DOI":"10.3389\/fimmu.2024.1498391","volume":"15","author":"P Jabbarzadeh Kaboli","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A. C-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol. 2024;15:1498391.","journal-title":"Front Immunol"},{"key":"2547_CR36","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/cancers15092626","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. C-Met mediated cytokine network promotes brain metastasis of breast cancer by remodeling neutrophil activities. Cancers (Basel). 2023;15:2626.","journal-title":"Cancers (Basel)"},{"key":"2547_CR37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","volume":"47","author":"N Glodde","year":"2017","unstructured":"Glodde N, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity. 2017;47:789-802.e9.","journal-title":"Immunity"},{"key":"2547_CR38","volume":"40","author":"S Zhang","year":"2023","unstructured":"Zhang S, Sun L, Zuo J, Feng D. Tumor associated neutrophils governs tumor progression through an IL-10\/STAT3\/PD-L1 feedback signaling loop in lung cancer. Transl Oncol. 2023;40:101866.","journal-title":"Transl Oncol"},{"key":"2547_CR39","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41:265.","journal-title":"J Exp Clin Cancer Res"},{"key":"2547_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2635","volume":"12","author":"A Prat","year":"2010","unstructured":"Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.","journal-title":"Breast Cancer Res"},{"key":"2547_CR41","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2547_CR42","volume":"12","author":"K Dias","year":"2017","unstructured":"Dias K, et al. Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE. 2017;12:e0168669.","journal-title":"PLoS ONE"},{"key":"2547_CR43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395\u20139.","journal-title":"Nature"},{"key":"2547_CR44","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","volume":"281","author":"MI Kontaridis","year":"2006","unstructured":"Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem. 2006;281:6785\u201392.","journal-title":"J Biol Chem"},{"key":"2547_CR45","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.18632\/oncotarget.23695","volume":"9","author":"C Gao","year":"2018","unstructured":"Gao C, et al. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018;9:5492\u2013508.","journal-title":"Oncotarget"},{"key":"2547_CR46","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1200\/JCO.2018.36.15_suppl.e13527","volume":"36","author":"S Maistro","year":"2018","unstructured":"Maistro S, et al. Cancer driver genes in luminal and triple negative breast cancer from young women. J Clin Oncol. 2018;36:e13527\u2013e13527.","journal-title":"J Clin Oncol"},{"key":"2547_CR47","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41388-020-1279-3","volume":"39","author":"J He","year":"2020","unstructured":"He J, et al. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression. Oncogene. 2020;39:4118\u201331.","journal-title":"Oncogene"},{"key":"2547_CR48","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41467-023-36790-9","volume":"14","author":"A De Falco","year":"2023","unstructured":"De Falco A, Caruso F, Su X-D, Iavarone A, Ceccarelli M. A variational algorithm to detect the clonal copy number substructure of tumors from scrna-seq data. Nat Commun. 2023;14:1074.","journal-title":"Nat Commun"},{"key":"2547_CR49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"2547_CR50","doi-asserted-by":"crossref","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.","journal-title":"Front Oncol"},{"key":"2547_CR51","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"2547_CR52","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41:265.","journal-title":"J Exp Clin Cancer Res"},{"key":"2547_CR53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181\u2013204.","journal-title":"Annu Rev Pathol"},{"key":"2547_CR54","first-page":"2885","volume":"25","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, et al. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Eur Rev Med Pharmacol Sci. 2021;25:2885\u201397.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2547_CR55","volume":"11","author":"H Yi","year":"2021","unstructured":"Yi H, et al. Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139.","journal-title":"Front Oncol"},{"key":"2547_CR56","volume":"37","author":"A Essalihi","year":"2025","unstructured":"Essalihi A, Bouchra O, Khadiri K, Khadrouf Z, Karkouri M. Immunotherapy for triple-negative breast cancer: current trends and future prospects. J Egypt Natl Cancer Inst. 2025;37:51.","journal-title":"J Egypt Natl Cancer Inst"},{"key":"2547_CR57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41523-023-00554-x","volume":"9","author":"A Thomas","year":"2023","unstructured":"Thomas A, Reis-Filho JS, Geyer CE, Wen HY. Rare subtypes of triple negative breast cancer: current understanding and future directions. NPJ Breast Cancer. 2023;9:55.","journal-title":"NPJ Breast Cancer"},{"key":"2547_CR58","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41467-020-15574-5","volume":"11","author":"C Fougner","year":"2020","unstructured":"Fougner C, Bergholtz H, Norum JH, S\u00f8rlie T. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020;11:1787.","journal-title":"Nat Commun"},{"key":"2547_CR59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"2547_CR60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","volume":"176","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181\u20138.","journal-title":"Eur J Cancer"},{"key":"2547_CR61","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20145664","volume":"11","author":"MK Muellner","year":"2015","unstructured":"Muellner MK, et al. Targeting a cell state common to triple-negative breast cancers. Mol Syst Biol. 2015;11:789.","journal-title":"Mol Syst Biol"},{"key":"2547_CR62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s13402-019-00452-0","volume":"42","author":"A Toma-Jonik","year":"2019","unstructured":"Toma-Jonik A, Vydra N, Janus P, Wid\u0142ak W. Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction. Cell Oncol Dordr Neth. 2019;42:579\u201389.","journal-title":"Cell Oncol Dordr Neth"},{"key":"2547_CR63","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","volume":"13","author":"C Marvalim","year":"2023","unstructured":"Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics. 2023;13:1421\u201342.","journal-title":"Theranostics"},{"key":"2547_CR64","doi-asserted-by":"crossref","first-page":"E1301","DOI":"10.1073\/pnas.1210353110","volume":"110","author":"JF Knight","year":"2013","unstructured":"Knight JF, et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A. 2013;110:E1301-1310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2547_CR65","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1038\/s41467-025-61034-3","volume":"16","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, et al. Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC. Nat Commun. 2025;16:6584.","journal-title":"Nat Commun"},{"key":"2547_CR66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","volume":"4","author":"AA Seyhan","year":"2019","unstructured":"Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles. Transl Med Commun. 2019;4:18.","journal-title":"Transl Med Commun"},{"key":"2547_CR67","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, et al. Patient derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov"},{"key":"2547_CR68","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","volume":"167","author":"A Bruna","year":"2016","unstructured":"Bruna A, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell. 2016;167:260-274.e22.","journal-title":"Cell"},{"key":"2547_CR69","doi-asserted-by":"crossref","first-page":"1560393","DOI":"10.3389\/fimmu.2025.1560393","volume":"16","author":"H Jin","year":"2025","unstructured":"Jin H, Meng X, Feng J. Mechanisms of tumor-associated macrophages in breast cancer and treatment strategy. Front Immunol. 2025;16:1560393.","journal-title":"Front Immunol"},{"key":"2547_CR70","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1038\/s41467-024-47433-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer. Nat Commun. 2024;15:3178.","journal-title":"Nat Commun"},{"key":"2547_CR71","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2024.42.16_suppl.9508","volume":"42","author":"SP Patel","year":"2024","unstructured":"Patel SP, et al. Safety and efficacy of first-in-class CXCR1\/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti\u2013PD-1 therapy. J Clin Oncol. 2024;42:9508\u20139508.","journal-title":"J Clin Oncol"},{"key":"2547_CR72","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.trecan.2020.06.005","volume":"6","author":"V Ramesh","year":"2020","unstructured":"Ramesh V, Brabletz T, Ceppi P. Targeting EMT in cancer with repurposed metabolic inhibitors. Trends Cancer. 2020;6:942\u201350.","journal-title":"Trends Cancer"},{"key":"2547_CR73","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41416-023-02394-9","volume":"129","author":"ND Machado","year":"2023","unstructured":"Machado ND, Heather LC, Harris AL, Higgins GS. Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities. Br J Cancer. 2023;129:897\u20139.","journal-title":"Br J Cancer"},{"key":"2547_CR74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02547-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:33:39Z","timestamp":1771418019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02547-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2547"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02547-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animal care and use in this study were approved by the local animal ethics committee, as mentioned in the Material and Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}